349 related articles for article (PubMed ID: 21854363)
21. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
22. Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1.
Pusl T; Vennegeerts T; Wimmer R; Denk GU; Beuers U; Rust C
Biochem Biophys Res Commun; 2008 Feb; 367(1):208-12. PubMed ID: 18164257
[TBL] [Abstract][Full Text] [Related]
23. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure.
De Marco G; Sordino D; Bruzzese E; Di Caro S; Mambretti D; Tramontano A; Colombo C; Simoni P; Guarino A
Aliment Pharmacol Ther; 2006 Jul; 24(2):387-94. PubMed ID: 16842466
[TBL] [Abstract][Full Text] [Related]
24. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
25. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy.
Meng LJ; Reyes H; Axelson M; Palma J; Hernandez I; Ribalta J; Sjövall J
Hepatology; 1997 Dec; 26(6):1573-9. PubMed ID: 9398000
[TBL] [Abstract][Full Text] [Related]
26. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
27. Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration.
Arrese M; Pizarro M; Solís N; Koenig C; Accatino L
Biochem Pharmacol; 1995 Oct; 50(8):1223-32. PubMed ID: 7488238
[TBL] [Abstract][Full Text] [Related]
28. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study.
Günsar C; Melek M; Karaca I; Sencan A; Mir E; Ortaç R; Canan O
Hepatogastroenterology; 2002; 49(44):497-500. PubMed ID: 11995481
[TBL] [Abstract][Full Text] [Related]
29. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
30. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
Alpini G; Baiocchi L; Glaser S; Ueno Y; Marzioni M; Francis H; Phinizy JL; Angelico M; Lesage G
Hepatology; 2002 May; 35(5):1041-52. PubMed ID: 11981754
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent.
Rodrigues CM; Steer CJ
Expert Opin Investig Drugs; 2001 Jul; 10(7):1243-53. PubMed ID: 11772248
[TBL] [Abstract][Full Text] [Related]
32. Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant biliary obstruction.
Bessone F; Roma MG
Ann Hepatol; 2016; 15(3):442-7. PubMed ID: 27049500
[TBL] [Abstract][Full Text] [Related]
33. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.
Serviddio G; Pereda J; Pallardó FV; Carretero J; Borras C; Cutrin J; Vendemiale G; Poli G; Viña J; Sastre J
Hepatology; 2004 Mar; 39(3):711-20. PubMed ID: 14999689
[TBL] [Abstract][Full Text] [Related]
35. Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture.
Hillaire S; Ballet F; Franco D; Setchell KD; Poupon R
Hepatology; 1995 Jul; 22(1):82-7. PubMed ID: 7601437
[TBL] [Abstract][Full Text] [Related]
36. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production.
Rodrigues CM; Fan G; Wong PY; Kren BT; Steer CJ
Mol Med; 1998 Mar; 4(3):165-78. PubMed ID: 9562975
[TBL] [Abstract][Full Text] [Related]
37. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
Scher H; Bishop WP; McCray PB
Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
[TBL] [Abstract][Full Text] [Related]
38. [Clinical pharmacology of ursodeoxycholic acid (UDCA)].
Kryczka W; Grieb P
Postepy Hig Med Dosw; 1994; 48(1):53-68. PubMed ID: 8058580
[TBL] [Abstract][Full Text] [Related]
39. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of hepatoprotective action of bile salts in liver disease.
Stiehl A; Benz C; Sauer P
Gastroenterol Clin North Am; 1999 Mar; 28(1):195-209, viii. PubMed ID: 10198785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]